In the Spring issue of Ms., our cover story by contributing editor Carrie Baker raises the alarm about future decisions from the Supreme Court. Her analysis could not be more timely. Right now, the Supreme Court is considering whether to allow mifepristone, one of two medications used in over 50 percent of all abortions in the U.S., to remain available under current FDA regulations that allow the drug to be prescribed by telemedicine and delivered through the mail and whether the generic version of the pill can remain on the market. A decision could come as early as this week.
|